

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 April 2009 (09.04.2009)

PCT

(10) International Publication Number
WO 2009/045224 A1

(51) International Patent Classification:
A61K 31/16 (2006.01)

(21) International Application Number:
PCT/US2007/080707

(22) International Filing Date: 8 October 2007 (08.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11/868,286 5 October 2007 (05.10.2007) US

(71) Applicant (for all designated States except US): **WINSTON LABORATORIES, INC.** [US/US]; 100 Fairway Drive, Suite 134, Vernon Hills, Illinois 60061 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BERNSTEIN, Joel** [US/US]; 615 Brier Hill Road, Deerfield, Illinois 60015 (US).

(74) Agents: **MARTIN, Alice O.** et al.; Barnes & Thornburg LLP, P.O. Box 2786, Chicago, Illinois 60690-2786 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(54) Title: METHOD FOR ALLEVIATING KERATOCONJUNCTIVITIS SICCA

(57) Abstract: An improved method of increasing tear production is by intranasally administering a therapeutically effective amount of a capsaicinoid compound to patients with deficient tear production. Optional incorporation into the intranasal formulation of a topical corticosteroid or topical anesthetic compound is used to reduce transient nasal stinging and burning which may sometimes accompany intranasal administration of capsaicinoids.



WO 2009/045224 A1